"The question to be asked
is if the current health care system can afford these high-cost medications. Is
the cost high because we will pay what cost has been set at, or is it based on
the cost to manufacture the product?"
— Winston Wong, Pharm.D., president of W-Squared Group, spoke
with AIS's Health Plan Weekly
about how payers are working to cover the high cost of Novartis' gene therapy
Zolgensma.
No comments:
Post a Comment